Valuation: Aclarion, Inc.

Market Cap 5.81M 5.03M 4.69M 4.31M 8.15M 553M 8.24M 55.13M 21.64M 276M 21.82M 21.34M 916M P/E 2026 *
-0.52x
P/E 2027 * -0.43x
Enterprise Value 5.81M 5.03M 4.69M 4.31M 8.15M 553M 8.24M 55.13M 21.64M 276M 21.82M 21.34M 916M EV / Sales 2026 *
43x
EV / Sales 2027 * 22.6x
Free-Float
73.8%
Yield 2026 *
-
Yield 2027 * -
1 day-0.84%
1 week+17.12%
Current month+4.89%
1 month-23.62%
3 months-26.25%
Current year-48.70%
1 week 1.99
Extreme 1.99
2.48
1 month 1.95
Extreme 1.95
3.17
Current year 1.95
Extreme 1.95
9.36
1 year 1.95
Extreme 1.95
12.03
3 years 1.95
Extreme 1.95
89,552.67
5 years 1.95
Extreme 1.95
586,115.57
10 years 1.95
Extreme 1.95
586,115.57
Manager TitleAgeSince
Chief Executive Officer 59 15/09/2021
Director of Finance/CFO 60 02/09/2025
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member 69 01/01/2016
Director/Board Member 55 01/09/2016
Chairman 61 21/04/2022
Date Insider Type Main position Quantity % Market Cap.
11/06/26 Free

Chairman

100,000 4.0613%
11/06/26 Free

Chief Financial Officer

50,000 2.0307%
26/11/25 Buy

Chief Executive Officer

10 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
-0.84%+17.12%-68.11%-100.00% 5.81M
+1.07%-0.74%+3.89%+15.59% 48.57B
+1.98%+9.05%+413.94%+532.17% 41.95B
+3.44%-4.65%+28.34%+8.81% 38.85B
+1.40%+0.10%+6.61%+61.93% 37.24B
+2.42%+5.72%+12.38%+44.79% 30.67B
-0.16%-3.11% - - 16.1B
+2.20%+0.48%+34.71%+127.15% 16.41B
+0.26%+1.84%+8.14%+18.97% 13.97B
+4.25%-8.23%-1.49%-35.46% 12.62B
Average +1.60%+1.01%+48.71%+74.88% 25.64B
Weighted average by Cap. +1.89%-0.12%+83.00%+120.72%

Financials

2026 *2027 *
Net sales 135K 117K 109K 100K 189K 12.84M 191K 1.28M 503K 6.42M 507K 496K 21.27M 257K 223K 207K 191K 360K 24.44M 364K 2.44M 957K 12.23M 965K 944K 40.5M
Net income -10.71M -9.27M -8.65M -7.95M -15.01M -1.02B -15.18M -102M -39.87M -509M -40.22M -39.33M -1.69B -13.47M -11.66M -10.87M -10M -18.88M -1.28B -19.09M -128M -50.15M -641M -50.58M -49.46M -2.12B
Net Debt - -
Logo Aclarion, Inc.
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
Employees
11
Date Price Change Volume
05/08/26 $2.360 -0.84% 23,347
04/08/26 $2.380 +0.85% 38,453
03/08/26 $2.360 +4.89% 57,775
31/07/26 $2.250 +11.39% 50,892
30/07/26 $2.020 +0.25% 78,235
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.360USD
Average target price
7.500USD
Spread / Average Target
+217.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACON Stock